AU627489B2 - The use of transglutaminases as immunosuppressants - Google Patents

The use of transglutaminases as immunosuppressants Download PDF

Info

Publication number
AU627489B2
AU627489B2 AU40904/89A AU4090489A AU627489B2 AU 627489 B2 AU627489 B2 AU 627489B2 AU 40904/89 A AU40904/89 A AU 40904/89A AU 4090489 A AU4090489 A AU 4090489A AU 627489 B2 AU627489 B2 AU 627489B2
Authority
AU
Australia
Prior art keywords
transglutaminase
patient
administering
effective amount
xiii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU40904/89A
Other languages
English (en)
Other versions
AU4090489A (en
Inventor
Norbert Heimburger
Hans Ulrich Schorlemmer
Thomas Stief
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL BEHRING GmbH
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of AU4090489A publication Critical patent/AU4090489A/en
Application granted granted Critical
Publication of AU627489B2 publication Critical patent/AU627489B2/en
Assigned to CENTEON PHARMA GMBH reassignment CENTEON PHARMA GMBH Alteration of Name(s) in Register under S187 Assignors: BEHRINGWERKE AKTIENGESELLSCHAFT
Assigned to AVENTIS BEHRING GMBH reassignment AVENTIS BEHRING GMBH Request to Amend Deed and Register Assignors: CENTEON PHARMA GMBH
Assigned to ZLB BEHRING GMBH reassignment ZLB BEHRING GMBH Request to Amend Deed and Register Assignors: AVENTIS BEHRING GMBH
Assigned to CSL BEHRING GMBH reassignment CSL BEHRING GMBH Request to Amend Deed and Register Assignors: ZLB BEHRING GMBH
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU40904/89A 1988-08-31 1989-08-30 The use of transglutaminases as immunosuppressants Expired AU627489B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3829524 1988-08-31
DE3829524A DE3829524A1 (de) 1988-08-31 1988-08-31 Verwendung von transglutaminasen als immunsuppressiva

Publications (2)

Publication Number Publication Date
AU4090489A AU4090489A (en) 1990-03-08
AU627489B2 true AU627489B2 (en) 1992-08-27

Family

ID=6361974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40904/89A Expired AU627489B2 (en) 1988-08-31 1989-08-30 The use of transglutaminases as immunosuppressants

Country Status (11)

Country Link
US (2) US5464615A (da)
EP (1) EP0358995B1 (da)
JP (1) JP2831045B2 (da)
KR (1) KR0154523B1 (da)
AT (1) ATE94762T1 (da)
AU (1) AU627489B2 (da)
CA (1) CA1338776C (da)
DE (2) DE3829524A1 (da)
DK (1) DK174512B1 (da)
ES (1) ES2059658T3 (da)
PT (1) PT91583B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva
DE3829523A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
JPH03240738A (ja) * 1990-02-20 1991-10-28 Hoechst Japan Ltd 糖尿病性壊疽治療剤
JP3550685B2 (ja) * 1992-04-21 2004-08-04 味の素株式会社 創傷治療剤
ATE184199T1 (de) * 1992-11-12 1999-09-15 Zymogenetics Inc Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
KR100302935B1 (ko) * 1993-03-30 2001-11-30 바트 루디거 사람혈액응고인자xiii과아프로티닌을포함하는약제학적조성물
DE19630557C2 (de) * 1996-07-18 1998-07-02 Schuppan Detlef Priv Doz Dr Dr Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Gewebe-Transglutaminase (tTG) sowie die Verwendung von tTG in Diagnose und Therapie
AU7483798A (en) * 1997-05-14 1998-12-08 Zymogenetics Inc. Use of factor xiii for the manufacture of a medicament for the treatment of reperfusion injury and mucosal damage
EP1201136A1 (en) * 2000-10-31 2002-05-02 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Food grade transglutaminase inhibitor and uses thereof
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP1889198B1 (en) 2005-04-28 2014-11-26 Proteus Digital Health, Inc. Pharma-informatics system
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2427178B1 (en) 2009-05-06 2023-01-04 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2017009136A1 (en) 2015-07-15 2017-01-19 Novo Nordisk Health Care Ag Factor xiii for the treatment of interstitial cystitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536387A (en) * 1982-02-12 1985-08-20 Unitika Ltd. Anti-cancer device
AU1138388A (en) * 1987-02-09 1988-08-11 Mycogen Plant Science, Inc. Hybrid rna virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT359652B (de) * 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
JPS63196520A (ja) * 1987-02-09 1988-08-15 Hoechst Japan Kk 潰瘍性大腸炎治療剤
US5013719A (en) * 1988-05-13 1991-05-07 Merrell Dow Pharmaceuticals Inc. Method of effecting immunosuppression
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536387A (en) * 1982-02-12 1985-08-20 Unitika Ltd. Anti-cancer device
AU1138388A (en) * 1987-02-09 1988-08-11 Mycogen Plant Science, Inc. Hybrid rna virus

Also Published As

Publication number Publication date
DE58905671D1 (de) 1993-10-28
JPH02108631A (ja) 1990-04-20
DK427989D0 (da) 1989-08-30
US5464615A (en) 1995-11-07
DK427989A (da) 1990-03-01
AU4090489A (en) 1990-03-08
EP0358995B1 (de) 1993-09-22
EP0358995A3 (en) 1990-08-16
PT91583A (pt) 1990-03-30
EP0358995A2 (de) 1990-03-21
ES2059658T3 (es) 1994-11-16
PT91583B (pt) 1995-05-31
DE3829524A1 (de) 1990-03-01
ATE94762T1 (de) 1993-10-15
US5695753A (en) 1997-12-09
KR900002802A (ko) 1990-03-23
DK174512B1 (da) 2003-05-05
KR0154523B1 (ko) 1998-11-16
CA1338776C (en) 1996-12-10
JP2831045B2 (ja) 1998-12-02

Similar Documents

Publication Publication Date Title
AU627489B2 (en) The use of transglutaminases as immunosuppressants
DE3789870T2 (de) Von thrombin abstammende polypeptid-zusammensetzungen und methoden für ihre benutzung.
EP0181465B2 (de) Blutgerinnungshemmende Proteine, Verfahren zur Herstellung sowie deren Verwendung
Melmon et al. Interaction of plasma kinins and granulocytes
JP6567147B2 (ja) 皮膚状態改善活性を有するペプチド及びその用途
DE69006851T2 (de) Blutgerinnungshemmende zusammensetzungen aus faktor xa.
DE3617752C2 (da)
JP2018518534A (ja) 治療方法
JPS59137417A (ja) 人尿由来コロニ−形成刺激因子及びカリクレインの製造法
AU616555B2 (en) The use of plasminogen activator inhibitor (pai-2) for immunosuppression
AU4565700A (en) Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
Tollefsen et al. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.
US20110212900A1 (en) Method for prophylactic and/or therapeutic treatment of pain associated with hematopoietic cell transplantation
Itoh et al. Heparin effects on superoxide production by neutrophils
Kline Plasminogen
JPH05503302A (ja) 巨核球成熟因子
DE3689927T2 (de) Reagens und Verfahren.
WEISS et al. Divergent effects of α1-antitrypsin on the regulation of iron metabolism in human erythroleukaemic (K562) and myelomonocytic (THP-1) cells
Bloomfield et al. Enhanced chemiluminescence production by phagocytosing neutrophils in psoriasis
US11975051B1 (en) Therapeutic peptides and uses thereof
Mil’to et al. Structure of rat testicles after intravenous injection of nanosized magnetite particles
Olas et al. Effect of granulocyte colony stimulating factor on pig blood platelets treated with cisplatin in vitro
JPS63190830A (ja) 抗悪性腫瘍剤
JPS59500673A (ja) 凝塊形成性の減少した血しよう蛋白質濃縮物およびそれらの臨床的交換治療における使用
Pintucci et al. Cathepsin G, a polymorphonuclear cell protease, is able to affect fibrinolytic system by releasing PAI-1 from endothelial cells

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: AVENTIS BEHRING GMBH

Free format text: FORMER NAME WAS: CENTEON PHARMA GMBH